Patients who have progressive tricuspid valve regurgitation after closure of ASD are noted. No previous studies in Asian population has been reported. Atrial septal defect, Tricuspid regurgitation, Transcatheter closure, ASD closure, Congenital heart defects
Conditions
Interventions
Transcutaneous closure by ASD device
Experimental Device
Transcutaneous closure of ASD
Sponsors
None listed
Eligibility
Sex/Gender
All
Age
3 Months to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients underwent transcatheter atrial septal defect (ASD) closure at the Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, between 2016 and 2022 with complete record form.
Exclusion criteria
Exclusion criteria: 1. Patients with patent foramen ovale (PFO), 2. Patients with congenital corrected transposition of great artery (ccTGA) 3. Patients who failed to perform transcutaneous ASD closure 4. Patients who were loss of follow up before 6 months post procedure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| outcome of severity of tricuspid valve regurgitation after closure with Transcutaneous atrial septal defect closure 1-3 years echocardiography | — |
Secondary
| Measure | Time frame |
|---|---|
| predisposing factor of patient with atrial septal defect that impact outcome of severity of tricuspid regurgitation 1-3 years collect baseline diseases of patient | — |
Countries
Thailand
Contacts
Public ContactKritvikrom Durongpisitkul
Faculty of Medicine Siriraj Hospital
Outcome results
None listed